Logo image of VVY.AS

VIVORYON THERAPEUTICS NV (VVY.AS) Stock Fundamental Analysis

AMS:VVY - Euronext Amsterdam - NL00150002Q7 - Common Stock - Currency: EUR

1.424  -0.04 (-2.73%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VVY. VVY was compared to 68 industry peers in the Biotechnology industry. VVY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VVY has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VVY has reported negative net income.
VVY had a negative operating cash flow in the past year.
VVY had negative earnings in each of the past 5 years.
VVY had a negative operating cash flow in each of the past 5 years.
VVY.AS Yearly Net Income VS EBIT VS OCF VS FCFVVY.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

VVY's Return On Assets of -182.28% is on the low side compared to the rest of the industry. VVY is outperformed by 85.29% of its industry peers.
VVY has a worse Return On Equity (-261.02%) than 63.24% of its industry peers.
Industry RankSector Rank
ROA -182.28%
ROE -261.02%
ROIC N/A
ROA(3y)-121.31%
ROA(5y)-94.21%
ROE(3y)-158.36%
ROE(5y)-122.89%
ROIC(3y)N/A
ROIC(5y)N/A
VVY.AS Yearly ROA, ROE, ROICVVY.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

VVY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VVY.AS Yearly Profit, Operating, Gross MarginsVVY.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

More info and screens

5

2. Health

2.1 Basic Checks

VVY does not have a ROIC to compare to the WACC, probably because it is not profitable.
VVY has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, VVY has more shares outstanding
VVY has a worse debt/assets ratio than last year.
VVY.AS Yearly Shares OutstandingVVY.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
VVY.AS Yearly Total Debt VS Total AssetsVVY.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

VVY has an Altman-Z score of -19.45. This is a bad value and indicates that VVY is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -19.45, VVY is not doing good in the industry: 79.41% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.01 indicates that VVY is not too dependend on debt financing.
VVY has a better Debt to Equity ratio (0.01) than 86.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -19.45
ROIC/WACCN/A
WACC7.19%
VVY.AS Yearly LT Debt VS Equity VS FCFVVY.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 7.20 indicates that VVY has no problem at all paying its short term obligations.
VVY has a better Current ratio (7.20) than 86.76% of its industry peers.
VVY has a Quick Ratio of 7.20. This indicates that VVY is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VVY (7.20) is better than 88.24% of its industry peers.
Industry RankSector Rank
Current Ratio 7.2
Quick Ratio 7.2
VVY.AS Yearly Current Assets VS Current LiabilitesVVY.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.46% over the past year.
The Revenue has grown by 100.00% in the past year. This is a very strong growth!
EPS 1Y (TTM)29.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.29%
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%100%

3.2 Future

VVY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 121.74% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y10.51%
EPS Next 2Y0.99%
EPS Next 3Y-5.86%
EPS Next 5Y121.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VVY.AS Yearly Revenue VS EstimatesVVY.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2023 2029 2030 0 500M 1B 1.5B
VVY.AS Yearly EPS VS EstimatesVVY.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 20 30 40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VVY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VVY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VVY.AS Price Earnings VS Forward Price EarningsVVY.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VVY.AS Per share dataVVY.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A cheap valuation may be justified as VVY's earnings are expected to decrease with -5.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.99%
EPS Next 3Y-5.86%

More info and screens

0

5. Dividend

5.1 Amount

VVY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVORYON THERAPEUTICS NV

AMS:VVY (7/14/2025, 3:54:24 PM)

1.424

-0.04 (-2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-22 2025-05-22
Earnings (Next)N/A N/A
Inst Owners13.06%
Inst Owner ChangeN/A
Ins Owners10.2%
Ins Owner ChangeN/A
Market Cap37.35M
Analysts82.5
Price Target5.23 (267.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.38%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.74
P/tB 5.32
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0
BVpS0.3
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -182.28%
ROE -261.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.31%
ROA(5y)-94.21%
ROE(3y)-158.36%
ROE(5y)-122.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.36%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.2
Quick Ratio 7.2
Altman-Z -19.45
F-Score2
WACC7.19%
ROIC/WACCN/A
Cap/Depr(3y)105.74%
Cap/Depr(5y)75.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.29%
EPS Next Y10.51%
EPS Next 2Y0.99%
EPS Next 3Y-5.86%
EPS Next 5Y121.74%
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.93%
EBIT Next 3Y7.35%
EBIT Next 5YN/A
FCF growth 1Y13.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.99%
OCF growth 3YN/A
OCF growth 5YN/A